We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $57.64, marking a -0.76% move from the previous day. This change lagged the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq lost 0.03%.
Prior to today's trading, shares of the pharmaceutical had gained 3.09% over the past month. This has outpaced the Medical sector's gain of 2.26% and the S&P 500's gain of 0.39% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release. In that report, analysts expect Astrazeneca to post earnings of $0.78 per share. This would mark year-over-year growth of 44.44%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 50.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.59 per share and revenue of $36.19 billion, which would represent changes of +28.86% and +35.95%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.34% higher. Astrazeneca is holding a Zacks Rank of #4 (Sell) right now.
Looking at its valuation, Astrazeneca is holding a Forward P/E ratio of 22.41. This represents a premium compared to its industry's average Forward P/E of 13.88.
We can also see that AZN currently has a PEG ratio of 1.26. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 160, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $57.64, marking a -0.76% move from the previous day. This change lagged the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq lost 0.03%.
Prior to today's trading, shares of the pharmaceutical had gained 3.09% over the past month. This has outpaced the Medical sector's gain of 2.26% and the S&P 500's gain of 0.39% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release. In that report, analysts expect Astrazeneca to post earnings of $0.78 per share. This would mark year-over-year growth of 44.44%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 50.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.59 per share and revenue of $36.19 billion, which would represent changes of +28.86% and +35.95%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.34% higher. Astrazeneca is holding a Zacks Rank of #4 (Sell) right now.
Looking at its valuation, Astrazeneca is holding a Forward P/E ratio of 22.41. This represents a premium compared to its industry's average Forward P/E of 13.88.
We can also see that AZN currently has a PEG ratio of 1.26. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 160, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.